| Fentanyl |
№ II-2555/18.07.2008 |
Victanyl 100 micrograms/h transdermal patches x 5, Transdermal patch, 100, mcg/h, Pack: 5 |
Actavis Group PTC ehf., Исландия |
Actavis Nordic A/S, Denmark |
113.79 |
22.76 |
136.55 |
6% |
6.83 |
120.62 |
24.12 |
144.74 |
18% |
20.48 |
141.1 |
28.22 |
169.32 |
|
КЦ-658/05.03.2009 |
19.03.2009 |
Неактивен |
1663 |
| Fentanyl |
№ II-2555/ 18.07.2008 |
Victanyl 25 micrograms/h transdermal patches x 5, Transdermal patch, 25, mcg/h, Pack: 5 |
Actavis Group PTC ehf., Исландия |
Actavis Group PTC ehf, Iceland |
13.03 |
2.61 |
15.64 |
6% |
0.78 |
13.81 |
2.76 |
16.57 |
18% |
2.35 |
16.16 |
3.23 |
19.39 |
промяна на обстоятелства НСР-3645/29.05.2014; цената е заличена с решение НСР-6479/18.06.2015 ( в сила от 16.07.2015 ) |
КЦРР-2430/22.02.2013 |
11.03.2013 |
Заличен |
1661 |
| Fentanyl |
№ II-2555/ 18.07.2008 |
Victanyl 25 micrograms/h transdermal patches x 5, Transdermal patch, 25, mcg/h, Pack: 5 |
Actavis Group PTC ehf., Исландия |
Actavis Nordic A/S, Denmark |
18.33 |
3.67 |
22 |
6% |
1.1 |
19.43 |
3.89 |
23.32 |
18% |
3.3 |
22.73 |
4.55 |
27.28 |
|
КЦРР-744/07.06.2012 |
24.06.2012 |
Неактивен |
1661 |
| Fentanyl |
№ II-2555/18.07.2008 |
Victanyl 25 micrograms/h transdermal patches x 5, Transdermal patch, 25, mcg/h, Pack: 5 |
Actavis Group PTC ehf., Исландия |
Actavis Nordic A/S, Denmark |
35.19 |
7.04 |
42.23 |
6% |
2.11 |
37.3 |
7.46 |
44.76 |
18% |
6.33 |
43.63 |
8.73 |
52.36 |
|
КЦ-658/05.03.2009 |
19.03.2009 |
Неактивен |
1661 |
| Fentanyl |
№ II-2555/ 18.07.2008 |
Victanyl 50 micrograms/h transdermal patches x 5, Transdermal patch, 50, mcg/h, Pack: 5 |
Actavis Group PTC ehf., Исландия |
Actavis Nordic A/S, Denmark |
34.81 |
6.96 |
41.77 |
4% |
1.39 |
36.2 |
7.24 |
43.44 |
16% |
5.57 |
41.77 |
8.35 |
50.12 |
|
КЦРР-744/07.06.2012 |
24.06.2012 |
Неактивен |
1662 |
| Fentanyl |
№ II-2555/18.07.2008 |
Victanyl 50 micrograms/h transdermal patches x 5, Transdermal patch, 50, mcg/h, Pack: 5 |
Actavis Group PTC ehf., Исландия |
Actavis Nordic A/S, Denmark |
63.53 |
12.71 |
76.24 |
6% |
3.81 |
67.34 |
13.47 |
80.81 |
18% |
11.44 |
78.78 |
15.76 |
94.54 |
|
КЦ-658/05.03.2009 |
19.03.2009 |
Неактивен |
1662 |
| Fentanyl |
№ II-2555/ 18.07.2008 |
Victanyl 75 micrograms/h transdermal patches x 5, Transdermal patch, 75, mcg/h, Pack: 5 |
Actavis Group PTC ehf., Исландия |
Actavis Nordic A/S, Denmark |
33.99 |
6.8 |
40.79 |
4% |
1.36 |
35.35 |
7.07 |
42.42 |
16% |
5.44 |
40.79 |
8.16 |
48.95 |
|
КЦРР-2432/22.02.2013 |
11.03.2013 |
Неактивен |
2767 |
| Fentanyl |
№ II-2555/ 18.07.2008 |
Victanyl 75 micrograms/h transdermal patches x 5, Transdermal patch, 75, mcg/h, Pack: 5 |
Actavis Group PTC ehf., Исландия |
Actavis Nordic A/S, Denmark |
54.98 |
11 |
65.98 |
4% |
2.2 |
57.18 |
11.44 |
68.62 |
16% |
8.8 |
65.98 |
13.2 |
79.18 |
|
КЦРР-744/07.06.2012 |
24.06.2012 |
Неактивен |
2767 |
| Fentanyl |
№ II-2555/18.07.2008 |
Victanyl 75 micrograms/h transdermal patches x 5, Transdermal patch, 75, mcg/h, Pack: 5 |
Actavis Group PTC ehf., Исландия |
Actavis Nordic A/S, Denmark |
92.32 |
18.46 |
110.78 |
6% |
5.54 |
97.86 |
19.57 |
117.43 |
18% |
16.62 |
114.48 |
22.9 |
137.38 |
|
КЦ-658/05.03.2009 |
19.03.2009 |
Неактивен |
2767 |
| Liraglutide |
EU/1/09/529/003 |
Victoza, Solution for injection, 6 mg/ ml - 3 ml, mg, Pack: 3 |
Novo Nordisk A/S, Дания |
Novo Nordisk a/s Denmark |
259.66 |
51.93 |
311.59 |
4% |
10 |
269.66 |
53.93 |
323.59 |
16% |
25 |
294.66 |
58.93 |
353.59 |
|
НСР-1688/11.11.2013 |
29.11.2013 |
Неактивен |
2269 |
| Liraglutide |
EU/1/09/529/003 |
Victoza, Solution for injection, 6 mg/ ml - 3 ml, mg, Pack: 3 |
Novo Nordisk A/S, Дания |
Novo Nordisk a/s Denmark |
260.52 |
52.1 |
312.62 |
4% |
10 |
270.52 |
54.1 |
324.62 |
16% |
25 |
295.52 |
59.1 |
354.62 |
|
КЦ-2544/09.08.2011 |
23.08.2011 |
Неактивен |
2269 |
| Liraglutide |
EU/1/09/529/003 |
VICTOZA, Solution for injection, 6 mg/ml - 3 ml, -, Pack: 3 pre-filled pens |
Novo Nordisk A/S, Дания |
Novo Nordisk a/s Denmark |
259.46 |
51.89 |
311.35 |
4% |
10 |
269.46 |
53.89 |
323.35 |
16% |
25 |
294.46 |
58.89 |
353.35 |
|
НСР-7853/15.01.2016. |
02.02.2016 |
Активен |
2269 |
| Boceprevir |
EU/1/11/704/001 |
Victrelis, Capsule, hard, 200, mg, Pack: 336 |
Merck Sharp & Dohme Ltd., Обединено Кралство |
S-P Labo NV Industriepark 30 B-2220 Heist-opden-Berg, Белгия |
4004.62 |
800.92 |
4805.54 |
4% |
10 |
4014.62 |
802.92 |
4817.54 |
16% |
25 |
4039.62 |
807.92 |
4847.54 |
|
НСР-8522/16.03.2016 |
31.03.2016 |
Активен |
3420 |
| Boceprevir |
EU/1/11/704/001 |
Victrelis, Capsule, hard, 200, mg, Pack: 336 |
Merck Sharp & Dohme Ltd., Обединено Кралство |
S-P Labo NV Industriepark 30 B-2220 Heist-opden-Berg, Белгия |
4831.13 |
966.23 |
5797.36 |
4% |
10 |
4841.13 |
968.23 |
5809.36 |
16% |
25 |
4866.13 |
973.23 |
5839.36 |
Оставена без разглеждане жалба от Комисия по прозрачност КП-115/03.12.2014 |
НСР-4659/25.09.2014 |
16.12.2014 |
Неактивен |
3420 |
| Boceprevir |
EU/1/11/704/001 |
Victrelis, Capsule, hard, 200, mg, Pack: 336 |
Merck Sharp & Dohme Ltd., Обединено Кралство |
S-P Labo NV Industriepark 30 B-2220 Heist-opden-Berg, Белгия |
5577.64 |
1115.53 |
6693.17 |
4% |
10 |
5587.64 |
1117.53 |
6705.17 |
16% |
25 |
5612.64 |
1122.53 |
6735.17 |
|
НСР-257/25.06.2014 |
30.07.2013 |
Неактивен |
3420 |
| Azacitidine |
EU/1/08/488/001 |
Vidaza, powder for suspension for injection, 25 mg/ml, mg, Pack: 1 vial x 100 mg |
Celgene Europe Limited, Обединено кралство, Обединено Кралство |
Baxter Oncology GmbH, Kantstrasse 2, 33790 Halle/Westfalen, Германия; Celgene Europe Ltd, 1 Longwalk Road, Stockley Park, Uxbridge, UB11 1DB, Обединено кралство |
622.62 |
124.52 |
747.14 |
4% |
10 |
632.62 |
126.52 |
759.14 |
16% |
25 |
657.62 |
131.52 |
789.14 |
|
НСР-7647/01.12.2015 (допуска предварително изпълнение) |
02.12.2015 |
Активен |
4121 |
| Didanosine |
II-0684/27.09.2007 |
VIDEX EC, Gastro‐resistant capsule, hard, 400, mg, Pack: 30 |
Bristol-Myers Squibb, Унгария |
Bristol-Myers Squibb, Champ “Lachaud”, La Goualle, F19250 Meymac, France |
232.47 |
46.49 |
278.96 |
4% |
9.3 |
241.77 |
48.35 |
290.12 |
16% |
25 |
266.77 |
53.35 |
320.12 |
|
КЦРР-1000/23.07.2012; НСР-9745/14.07.2016 |
02.08.2016. |
Заличен |
1291 |
| Didanosine |
II-0681/27.09.2007 |
VIDEX EC, Gastro‐resistant capsule, hard, 250, mg, Pack: 30 |
Bristol-Myers Squibb, Унгария |
Bristol-Myers Squibb, Champ “Lachaud”, La Goualle, F19250 Meymac, France |
145.3 |
29.06 |
174.36 |
4% |
5.81 |
151.11 |
30.22 |
181.33 |
16% |
23.25 |
174.36 |
34.87 |
209.23 |
|
КЦРР-1000/23.07.2012; НСР-9746/14.07.2016 |
02.08.2016. |
Заличен |
1290 |
| Didanosine |
II-0684/27.09.2007 |
VIDEX EC, Gastro‐resistant capsule, hard, 400, mg, Pack: 30 |
Bristol-Myers Squibb, Унгария |
Bristol-Myers Squibb, Champ “Lachaud”, La Goualle, F19250 Meymac, France |
301.94 |
60.39 |
362.33 |
6% |
15 |
316.94 |
63.39 |
380.33 |
18% |
30 |
346.94 |
69.39 |
416.33 |
|
КЦ-682/06.03.2009 |
23.03.2009 |
Неактивен |
1291 |
| Didanosine |
II-0681/27.09.2007 |
VIDEX EC, Gastro‐resistant capsule, hard, 250, mg, Pack: 30 |
Bristol-Myers Squibb, Унгария |
Bristol-Myers Squibb, Champ “Lachaud”, La Goualle, F19250 Meymac, France |
188.7 |
37.74 |
226.44 |
6% |
11.32 |
200.02 |
40 |
240.02 |
18% |
30 |
230.02 |
46 |
276.02 |
|
КЦ-682/06.03.2009 |
23.03.2009 |
Неактивен |
1290 |
| Ombitasvir, paritaprevir and ritonavir |
EU/1/14/982/001 |
Viekirax, Film‐coated tablet, 12,5 mg/75 mg/50 mg, mg, Pack: 56 |
AbbVie Ltd, Обединено Кралство |
AbbVie Deutschland GmbH & Co. KG, Knollstrasse 67061 Ludwigshafen, Германия |
25191.09 |
5038.22 |
30229.31 |
4% |
10 |
25201.09 |
5040.22 |
30241.31 |
16% |
25 |
25226.09 |
5045.22 |
30271.31 |
корекционно решение НСР-7662/01.12.2015 |
НСР-7449/10.11.2015. (предварително изпълнение) |
10.11.2015 |
Неактивен |
4091 |
| Cholecalciferol |
№ II-10950/01.06.2005 |
VIGANTOL OIL, -, 0, 5 mg/ml - 10 ml, mg, Pack: 1 |
Merck KGaA, Германия |
Merck K GaA - Germany |
1.9 |
0.38 |
2.28 |
7% |
0.13 |
2.03 |
0.41 |
2.44 |
20% |
0.38 |
2.41 |
0.48 |
2.89 |
цената се заличава КЦРР-1519/25.10.2012 |
КЦ-1944/25.01.2011 |
17.02.2011 |
Заличен |
1012 |
| Lacosamide |
EU/1/08/470/008 |
VIMPAT, Film‐coated tablet, 150, mg, Pack: 56 |
UCB Pharma SA, Белгия |
AESICA Pharmaceuticals GmbH, Germany; UCB Pharma SA, Belgium |
179.92 |
35.98 |
215.9 |
4% |
7.2 |
187.12 |
37.42 |
224.54 |
16% |
25 |
212.12 |
42.42 |
254.54 |
|
НСР-8225/22.02.2016 |
09.03.2016 |
Активен |
3398 |
| Lacosamide |
EU/1/08/470/011 |
VIMPAT, Film‐coated tablet, 200, mg, Pack: 56 |
UCB Pharma SA, Белгия |
AESICA Pharmaceuticals GmbH, Germany; UCB Pharma SA, Belgium |
240.02 |
48 |
288.02 |
4% |
9.6 |
249.62 |
49.92 |
299.54 |
16% |
25 |
274.62 |
54.92 |
329.54 |
|
НСР-8224/22.02.2016 |
09.03.2016 |
Активен |
3399 |
| Lacosamide |
EU/1/08/470/005 |
VIMPAT, Film‐coated tablet, 100, mg, Pack: 56 |
UCB Pharma SA, Белгия |
AESICA Pharmaceuticals GmbH, Germany; UCB Pharma SA, Belgium |
120.09 |
24.02 |
144.11 |
4% |
4.8 |
124.89 |
24.98 |
149.87 |
16% |
19.21 |
144.1 |
28.82 |
172.92 |
|
НСР-8226/22.02.2016 |
09.03.2016 |
Активен |
3397 |